# A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

> **NCT00284804** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 74 (actual)

## Conditions studied

- Hodgkin's Disease

## Interventions

- **DRUG:** MDX-060

## Key facts

- **NCT ID:** NCT00284804
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-05
- **Final completion:** 2009-10
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284804, "A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00284804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*